Related Experiment Video

Updated: Aug 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Receptor tyrosine kinases as target for anti-cancer therapy

S Brunelleschi1, L Penengo, M M Santoro

  • 1University of Piemonte Orientale A.Avogadro, Department of Medical Sciences, Novara, Italy.

Current Pharmaceutical Design
|August 13, 2002
PubMed

Insights

Receptor tyrosine kinases (RTKs) are crucial in cell signaling and cancer. Inhibiting RTKs and targeting the Cbl protein offers new therapeutic strategies for malignancies.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Oncology

Background:

  • Receptor tyrosine kinases (RTKs) are cell surface proteins mediating signal transduction pathways.
  • RTK dysregulation (over-expression, alteration) is linked to human cancers, driving tumor growth, angiogenesis, and metastasis.
  • RTKs are established targets for cancer therapy, with numerous inhibitors developed and in clinical use.

Purpose of the Study:

  • To explore the role of RTKs in cancer development and therapeutic strategies.
  • To highlight the significance of ligand-dependent RTK downregulation for activity modulation.
  • To identify novel pharmacological targets for treating RTK-driven malignancies.

Main Methods:

  • Review of existing literature on RTK signaling pathways and their role in cancer.
  • Analysis of the function of adaptor protein Cbl in the negative regulation of RTKs.
  • Evaluation of small molecule RTK inhibitors in preclinical and clinical settings.

Main Results:

  • RTKs are critical mediators of cell responses, including proliferation and survival, which are often hijacked by cancer cells.
  • The adaptor protein Cbl plays a key role in the negative regulation and downregulation of RTKs like EGF and HGF receptors.
  • Development of small molecule RTK inhibitors has yielded successful therapeutic agents and ongoing clinical trials.

Conclusions:

  • RTKs are pivotal targets in cancer therapy due to their involvement in oncogenesis.
  • Targeting RTK downregulation mechanisms, particularly involving the Cbl protein, presents a promising avenue for novel cancer treatments.
  • Further research into RTK signaling and regulatory proteins like Cbl can lead to more effective therapies for human malignancies.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.